Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Berthold, Heiner K ^a   Seidah, Nabil G ^b   Benjannet, Suzanne ^b   Gouni Berthold, Ioanna ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; CAMPESTEROL; CHOLESTENOL; DESMOSTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LATHOSTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MESSENGER RNA; NIEMANN PICK C1 LIKE PROTEIN 1; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SIMVASTATIN; SITOSTEROL; STEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BODY COMPOSITION; BODY MASS; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ENZYME BLOOD LEVEL; EVIDENCE BASED MEDICINE; FASTING GLUCOSE; FASTING INSULIN; GLOMERULUS FILTRATION RATE; HOMA INDEX; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC PARAMETERS; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; STEROL ANALYSIS; THYROID FUNCTION; UPREGULATION;

ADULT; AZETIDINES; CHOLESTEROL, LDL; HUMANS; MALE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; SIMVASTATIN; UP-REGULATION;

EID: 84875474072     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060095     Document Type: Article

References (32)

1. Gouni-Berthold I, Berthold HK, Gylling H, Hallikainen M, Giannakidou E, et al. (2008) Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis 198: 198-207.
2. Seidah NG, Prat A, (2012) The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11: 367-383.
3. Davignon J, Dubuc G, (2009) Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc 120: 163-173.
4. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354: 1264-1272. 354/12/1264 [pii];10.1056/NEJMoa054013 [doi].
5. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, et al. (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 24: 1454-1459. 10.1161/01.ATV.0000134621.14315.43 [doi];01.ATV.0000134621.14315.43 [pii].
6. Huijgen R, Boekholdt SM, Arsenault BJ, Bao W, Davaine JM, et al. (2012) Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol 59: 1778-1784. S0735-1097(12)00795-4 [pii];10.1016/j.jacc.2011.12.043 [doi].
7. Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL (2011) Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 21: 835-843. S0939-4753(11)00161-X [pii];10.1016/j.numecd.2011.06.002 [doi].
8. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, et al. (2008) Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 49: 394-398. M700437-JLR200 [pii];10.1194/jlr.M700437-JLR200 [doi].
9. Seidah NG (2009) PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets 13: 19-28. 10.1517/14728220802600715 [doi].
10. Awan Z, Seidah NG, MacFadyen JG, Benjannet S, Chasman DI, et al. (2012) Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem 58: 183-189. clinchem.2011.172932 [pii];10.1373/clinchem.2011.172932 [doi].
11. Konrad RJ, Troutt JS, Cao G (2011) Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis 10: 38. 1476-511X-10-38 [pii];10.1186/1476-511X-10-38 [doi].
12. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, et al. (2010) Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J 31: 1633-1639. ehq181 [pii];10.1093/eurheartj/ehq181 [doi].
13. Berthold HK, Naini A, Di Mauro S, Hallikainen M, Gylling H, et al. (2006) Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf 29: 703-712.
14. Dubuc G, Tremblay M, Pare G, Jacques H, Hamelin J, et al. (2010) A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 51: 140-149. M900273-JLR200 [pii];10.1194/jlr.M900273-JLR200 [doi].
15. Nassoury N, Blasiole DA, Tebon OA, Benjannet S, Hamelin J, et al. (2007) The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR. Traffic 8: 718-732.
16. Gouni-Berthold I, Berthold HK, Chamberland JP, Krone W, Mantzoros CS (2008) Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf) 68: 536-541. CEN3080 [pii];10.1111/j.1365-2265.2007.03080.x [doi].
17. Miettinen TA, Tilvis RS, Kesaniemi YA, (1990) Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 131: 20-31.
18. Berge KE, Ose L, Leren TP (2006) Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 26: 1094-1100. 01.ATV.0000204337.81286.1c [pii];10.1161/01.ATV.0000204337.81286.1c [doi].
19. Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, et al. (2005) Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 25: 2654-2660. 01.ATV.0000190668.94752.ab [pii];10.1161/01.ATV.0000190668.94752.ab [doi].
20. Lakoski SG, Xu F, Vega GL, Grundy SM, Chandalia M, et al. (2010) Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab 95: 800-809. jc.2009-1952 [pii];10.1210/jc.2009-1952 [doi].
21. Han L, Li M, Liu Y, Han C, Ye P (2012) Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator-activated receptors in rats. Pharmacology 89: 74-82. 000335783 [pii];10.1159/000335783[doi].
22. Sanderson LM, Boekschoten MV, Desvergne B, Muller M, Kersten S (2010) Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver. Physiol Genomics 41: 42-52. 00127.2009 [pii];10.1152/physiolgenomics.00127.2009 [doi].
23. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, et al. (2010) High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 51: 2714-2721. jlr.M008144 [pii];10.1194/jlr.M008144 [doi].
24. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, et al. (2001) Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 110: 352-360. S0002-9343(01)00638-6 [pii].
25. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, et al. (2001) Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 23: 1209-1230.
26. Aggarwal D, Freake HC, Soliman GA, Dutta A, Fernandez ML (2006) Validation of using gene expression in mononuclear cells as a marker for hepatic cholesterol metabolism. Lipids Health Dis 5: 22. 1476-511X-5-22 [pii];10.1186/1476-511X-5-22 [doi].
27. Powell EE, Kroon PA (1994) Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in human liver. J Clin Invest 93: 2168-2174. 10.1172/JCI117213 [doi].
28. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM (2008) Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 118: 355-362. CIRCULATIONAHA.108.773267 [pii];10.1161/CIRCULATIONAHA.108.773267 [doi].
29. Pocathikorn A, Taylor RR, Mamotte CD (2010) Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells. Clin Exp Pharmacol Physiol 37: 471-476. CEP5337 [pii];10.1111/j.1440-1681.2009.05337.x [doi].
30. Jones JL, Park Y, Lee J, Lerman RH, Fernandez ML (2011) A Mediterranean-style, low-glycemic-load diet reduces the expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in mononuclear cells and plasma insulin in women with metabolic syndrome. Nutr Res 31: 659-664. S0271-5317(11)00157-6 [pii];10.1016/j.nutres.2011.08.011 [doi].
31. Monte AA, Vasiliou V, Heard KJ (2012) Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice. J Pharmacogenomics Pharmacoproteomics S5.
32. de Mello VD, Kolehmanien M, Schwab U, Pulkkinen L, Uusitupa M (2012) Gene expression of peripheral blood mononuclear cells as a tool in dietary intervention studies: What do we know so far? Mol Nutr Food Res 56: 1160-1172. 10.1002/mnfr.201100685 [doi].